EG24180A - Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer - Google Patents

Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Info

Publication number
EG24180A
EG24180A EG20010660A EG20010660A EG24180A EG 24180 A EG24180 A EG 24180A EG 20010660 A EG20010660 A EG 20010660A EG 20010660 A EG20010660 A EG 20010660A EG 24180 A EG24180 A EG 24180A
Authority
EG
Egypt
Prior art keywords
farnesyl transferase
transferase inhibiting
quinoline enantiomer
annelated quinoline
annelated
Prior art date
Application number
EG20010660A
Other languages
English (en)
Inventor
Marc G Venet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of EG24180A publication Critical patent/EG24180A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EG20010660A 2000-06-22 2001-06-20 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer EG24180A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22

Publications (1)

Publication Number Publication Date
EG24180A true EG24180A (en) 2008-09-28

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010660A EG24180A (en) 2000-06-22 2001-06-20 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Country Status (34)

Country Link
US (3) US20030114471A1 (es)
EP (1) EP1296984B1 (es)
JP (1) JP4919575B2 (es)
KR (2) KR100846370B1 (es)
CN (1) CN1207296C (es)
AR (1) AR030704A1 (es)
AT (1) ATE294804T1 (es)
AU (3) AU6396201A (es)
BG (1) BG65894B1 (es)
BR (1) BRPI0111743B8 (es)
CA (1) CA2410232C (es)
CZ (1) CZ295278B6 (es)
DE (1) DE60110592T2 (es)
EA (1) EA005065B1 (es)
EE (1) EE04966B1 (es)
EG (1) EG24180A (es)
ES (1) ES2241830T3 (es)
HK (1) HK1058363A1 (es)
HR (1) HRP20020989B1 (es)
HU (1) HU229095B1 (es)
IL (2) IL153560A0 (es)
IS (1) IS2596B (es)
JO (1) JO2361B1 (es)
MX (1) MXPA02012845A (es)
MY (1) MY127734A (es)
NO (1) NO324494B1 (es)
NZ (1) NZ522481A (es)
PA (1) PA8519501A1 (es)
PL (1) PL209521B1 (es)
SA (1) SA01220349B1 (es)
SK (1) SK285699B6 (es)
UA (1) UA73572C2 (es)
WO (1) WO2001098302A1 (es)
ZA (1) ZA200210305B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
JP4384505B2 (ja) 2002-04-15 2009-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
ES2787073T3 (es) 2015-08-17 2020-10-14 Kura Oncology Inc Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa
HUE053927T2 (hu) 2016-11-03 2021-07-28 Kura Oncology Inc Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
CZ293296B6 (cs) * 1995-12-08 2004-03-17 Janssen Pharmaceutica N.V. (Imidazol-5-yl)methyl-2-chinolinonové deriváty inhibující farnesyl protein transferázu
WO1997036876A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ATE366250T1 (de) * 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv Chinazolinone die farnesyltransferase hemmen
ES2182327T3 (es) 1997-06-02 2003-03-01 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos.
BR9911869A (pt) 1998-07-06 2001-03-27 Janssen Pharmaceutica Nv Inibidores da transferase da proteìna farnesil para o tratamento das artropatias
EE04582B1 (et) * 1998-07-06 2006-02-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis
BR9913315A (pt) * 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
AU4925499A (en) * 1998-08-27 2000-03-21 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
PL199080B1 (pl) * 1998-12-23 2008-08-29 Janssen Pharmaceutica Nv Pochodna chinoliny o pierścieniu 1,2-skondensowanym i sposób jej otrzymywania, kompozycja farmaceutyczna i sposób jej otrzymywania, pochodna chinoliny i sposób jej otrzymywania
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
TR200201296T2 (tr) * 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2001062234A2 (en) 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
WO2002024687A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives

Also Published As

Publication number Publication date
BR0111743A (pt) 2003-07-08
HUP0300872A2 (hu) 2003-07-28
JP4919575B2 (ja) 2012-04-18
KR100831940B1 (ko) 2008-05-23
HRP20020989A2 (en) 2005-02-28
KR20070121847A (ko) 2007-12-27
NZ522481A (en) 2004-09-24
IL153560A (en) 2011-06-30
AR030704A1 (es) 2003-09-03
CZ295278B6 (cs) 2005-06-15
DE60110592D1 (de) 2005-06-09
NO20026032D0 (no) 2002-12-16
CN1207296C (zh) 2005-06-22
EA005065B1 (ru) 2004-10-28
PA8519501A1 (es) 2002-08-29
CA2410232C (en) 2008-10-07
US20070259902A1 (en) 2007-11-08
ATE294804T1 (de) 2005-05-15
US8329714B2 (en) 2012-12-11
UA73572C2 (en) 2005-08-15
KR20030009463A (ko) 2003-01-29
WO2001098302A1 (en) 2001-12-27
PL209521B1 (pl) 2011-09-30
NO20026032L (no) 2002-12-16
EP1296984B1 (en) 2005-05-04
CZ2003114A3 (cs) 2003-05-14
JP2004501153A (ja) 2004-01-15
EE04966B1 (et) 2008-02-15
PL358918A1 (en) 2004-08-23
SK285699B6 (sk) 2007-06-07
AU2006220405A1 (en) 2006-10-12
CN1437601A (zh) 2003-08-20
IS2596B (is) 2010-03-15
US8318753B2 (en) 2012-11-27
SK502003A3 (en) 2003-05-02
IL153560A0 (en) 2003-07-06
ZA200210305B (en) 2004-03-19
HU229095B1 (en) 2013-07-29
CA2410232A1 (en) 2001-12-27
EP1296984A1 (en) 2003-04-02
HRP20020989B1 (en) 2011-05-31
MY127734A (en) 2006-12-29
IS6590A (is) 2002-10-25
BG65894B1 (bg) 2010-04-30
AU6396201A (en) 2002-01-02
KR100846370B1 (ko) 2008-07-15
EE200200695A (et) 2004-06-15
SA01220349B1 (ar) 2007-01-23
BG107310A (bg) 2003-07-31
BRPI0111743B8 (pt) 2021-05-25
BRPI0111743B1 (pt) 2019-03-26
US20080114009A1 (en) 2008-05-15
JO2361B1 (en) 2006-12-12
ES2241830T3 (es) 2005-11-01
US20030114471A1 (en) 2003-06-19
AU2006220405B2 (en) 2009-05-21
DE60110592T2 (de) 2006-01-19
EA200300048A1 (ru) 2003-04-24
MXPA02012845A (es) 2003-05-15
HK1058363A1 (en) 2004-05-14
HUP0300872A3 (en) 2004-11-29
AU2001263962B2 (en) 2006-07-20
NO324494B1 (no) 2007-10-29

Similar Documents

Publication Publication Date Title
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
MY145332A (en) Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
RS20060004A (en) Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
EG24180A (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
DE50211929D1 (en) Pyrimidinderivate
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
WO2000001415A3 (en) Use of inhibitors of protein kinase c epsilon to treat pain
WO2001060458A3 (en) Inhibitors of prenyl-protein transferase
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
MY122477A (en) Sertraline oral concentrate
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
HUP0301915A2 (hu) Sildenafil és egyéb PDE5 inhibitor hatású vegyületek alkalmazása korai magömlés kezelésére szolgáló gyógyszerkészítmény elżállítására
TH59553B (th) 1,2-แอนเนเลเทด ควิโนลีน อิแนนซิโอเมอร์ ซึ่งมีฤทธิ์ยับยั้งฟาร์เนซิลทรานส์เฟอเรส